Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3272 - Association of LIPI Score with Immune Checkpoint Inhibitors (ICI) outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck (R/M SCCHN) patients (pts).

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Ruth Gabriela Herrera Gomez

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

R.G. Herrera Gomez1, L. Mezquita Pérez2, E. Auclin3, K. Saleh2, N. Baste Rotllan1, M. Iacobs1, S.C. Bursuc1, L. Mayache Badis1, F.R. Ferrand4, O. Casiraghi5, S. Temam1, I. Breuskin1, Y. Tao6, B. Besse7, C. Even1

Author affiliations

  • 1 Department Of Head And Neck Surgical & Medical Oncology, Gustave Roussy Institute, 94800 - Villejuif/FR
  • 2 Department Of Medical Oncology, Gustave Roussy Institute, 94800 - Villejuif/FR
  • 3 Medical Oncology, European Hospital Georges Pompidou, 75015 - Paris/FR
  • 4 Medical Oncology, Bégin Military Teaching Hospital, 94160 - Saint-Mandé/FR
  • 5 Department Of Biopathology, Gustave Roussy Institute, 94800 - Villejuif/FR
  • 6 Department Of Radiation-oncology, Gustave Roussy Institute, 94800 - Villejuif/FR
  • 7 Department Of Medical Oncology, Gustave Roussy Institute, 9494805 - Villejuif/FR
More

Resources

Abstract 3272

Background

Lung Immune Prognosis Index (LIPI), based on pretreatment dNLR (neutrophils/(leucocytes-neutrophils)) and LDH, correlated with outcome after immune checkpoint inhibitors (ICI) in advanced NSCLC pts. We tested if LIPI, could have the same role in R/M SCCHN pts.

Methods

We conducted a retrospective study of 86 R/M HNSCC pts treated with ICI in our institution between Sep 2014 and Dec 2017. Complete blood cell counts and LDH were collected before ICI treatment. LIPI characterized 3 groups: good risk if dNLR < 3 and normal LDH, intermediate if dNLR > 3 or LDH > upper limit of normal (ULN), and poor if dNLR >3 and LDH >ULN. ICI benefit was analyzed according to overall survival (OS) and progression free survival (PFS).

Results

In our cohort, 65 pts (76%) were males, 61 (71%) current/former smokers, 81 (94%) had PS ≤ 1, with median age 59 years. According to the location: 19 (22%) had oral cavity carcinoma, 43 (50%) oropharynx, 11 (13%) hypopharynx and 13 (15%) larynx. HPV by immunohistochemistry was positive in 11/52 pts (10 oropharynx, 1 oral cavity). Twenty-eight (33%) pts received PD1, PDL1, or CTLA-4 inhibitors in monotherapy, and 58 (67%) in combination. The median of prior lines was 1 (0-6). The median follow-up was 8 months (m) [95% CI:7-12], median PFS 3 m [95% CI:2-4] and median OS 12 m [95% CI 8-NA]. The dNLR >3 (36%) and LDH >ULN (10%) were associated with poor OS (P = 0.005). Based on them, LIPI considered: 44 pts (51%) as good, 38 (44%) intermediate and 4 (5%) poor prognosis group. LIPI was an independent factor for OS (hazard ratio [HR 2.49, 95% CI 1.2-5.2] for intermediate LIPI and [HR 7.97, 95%CI 1.9-32.6] for poor LIPI, P = 0.005) and PFS (P = 0.004). Median OS for poor, intermediate, and good LIPI was 3.5 m [95% CI, 2- not reached (NR)], 7 m (95% CI, 5-NR), and 12 m (95% CI, 8-NR), respectively (P = 0.003).

Conclusions

High LIPI was correlated with worse ICI outcomes in R/M SCCHN pts. Further studies are warranted to confirm the prognostic impact of this score and the potential predictive role for ICI.

Clinical trial identification

Legal entity responsible for the study

Caroline Even.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.